CoChat

Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR -Amplified Gastroesophageal Adenocarcinoma

Open access
Maron, Steven B., Alpert, Lindsay, Kwak, Heewon A., Lomnicki, Samantha, Chase, Leah, Xu, David, O'Day, Emily, Nagy, Rebecca J., Lanman, Richard B., Cecchi, Fabiola, Hembrough, Todd, Schrock, Alexa, Hart, John, Xiao, Shu-Yuan, Setia, Namrata, Catenacci, Daniel V.T. · 2018 · Cancer Discovery
Cited by 124

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Previous anti-EGFR trials in unselected patients with gastroesophageal adenocarcinoma (GEA) were resoundingly negative. We identified EGFR amplification in 5% (19/363) of patients at the University of Chicago, including 6% (8/140) who were prospectively screened with intention-to-treat using anti-EGFR therapy. Seven patients received ≥1 dose of treatment: three first-line FOLFOX plus ABT-806, one second-line FOLFIRI plus cetuximab, and three third/fourth-line cetuximab alone. Treatment achieved objective response in 58% (4/7) and disease control in 100% (7/7) with a median progression-free survival of 10 months. Pretreatment and posttreatment tumor next-generation sequencing (NGS), serial plasma circulating tumor DNA (ctDNA) NGS, and tumor IHC/FISH for EGFR revealed preexisting and/or acquired genomic events, including EGFR-negative clones, PTEN deletion, KRAS amplification/mutation, NRAS, MYC, and HER2 amplification, and GNAS mutations serving as mechanisms of resistance. Two evaluable patients demonstrated interval increase of CD3+ infiltrate, including one who demonstrated increased NKp46+, and PD-L1 IHC expression from baseline, suggesting an immune therapeutic mechanism of action. EGFR amplification predicted benefit from anti-EGFR therapy, albeit until various resistance mechanisms emerged. Significance: This paper highlights the role of EGFR inhibitors in EGFR-amplified GEA—despite negative results in prior unselected phase III trials. Using serial ctDNA and tissue NGS, we identified mechanisms of primary and acquired resistance in all patients, as well as potential contribution of antibody-dependent cell-mediated cytotoxicity to their clinical benefit. Cancer Discov; 8(6); 696–713. ©2018 AACR. See related commentary by Strickler, p. 679. This article is highlighted in the In This Issue feature, p. 663

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-17-1260

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 124

Metadata

Authors
Maron, S. B., Alpert, L., Kwak, H. A., Lomnicki, S., Chase, L., Xu, D., O'Day, E., Nagy, R. J., Lanman, R. B., Cecchi, F., Hembrough, T., Schrock, A., Hart, J., Xiao, S.-Y., Setia, N., & Catenacci, D. V. T.
Venue
Cancer Discovery
Published
2018-05-31
Volume
8
Issue
6
Pages
696-713
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2793114790
Cited by
124
References
19
FWCI
12.17
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR -Amplified Gastroesophageal Adenocarcinoma. https://app.cochat.ai/papers/10.1158/2159-8290.cd-17-1260
The paper
Maron, S. B., Alpert, L., Kwak, H. A., Lomnicki, S., Chase, L., Xu, D., O'Day, E., Nagy, R. J., Lanman, R. B., Cecchi, F., Hembrough, T., Schrock, A., Hart, J., Xiao, S.-Y., Setia, N., & Catenacci, D. V. T. (2018). Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR -Amplified Gastroesophageal Adenocarcinoma. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-17-1260

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.